top of page
  • Writer's pictureAnupam Jena

Top 10 Most Popular Stories for May 2024 from TCTMD


TCTMD's top 10 stories for May 2024 encapsulate significant developments and discussions in cardiovascular medicine. The highlights range from breakthrough clinical trials to innovative procedural techniques, providing insights into the evolving landscape of interventional cardiology.

Detailed Analysis

1. TAVI vs Surgery in Aortic Stenosis Plus CAD

This story discusses the surprising results from a recent trial at EuroPCR, where transcatheter aortic valve implantation (TAVI) showed superior outcomes compared to surgery in patients with aortic stenosis and coronary artery disease (CAD). While interventionalists were encouraged by these findings, surgeons emphasized the need to scrutinize the data closely to understand the full implications of these results. The debate highlights the ongoing evolution and competition between less invasive and traditional surgical approaches in complex cardiovascular conditions.

2. FLOW Trial: Semaglutide’s Impact on Diabetic Patients with CKD

The FLOW trial has shown that semaglutide, a glucagon-like peptide-1 receptor agonist, significantly reduces major kidney disease events by 24% and major adverse cardiovascular events (MACE) by 18% in patients with diabetes and chronic kidney disease (CKD). These results are particularly important as they offer a promising therapeutic option for a high-risk patient population, potentially transforming the management of diabetes and CKD.

3. DanGer Shock Trial: Impella in AMICS

The DanGer Shock trial provided strong evidence supporting the use of the Impella device in acute myocardial infarction with cardiogenic shock (AMICS). Following the trial's success, the focus has shifted towards minimizing complications associated with the device. Strategies under consideration include the development of smaller, more efficient devices and the establishment of stringent procedural protocols to enhance patient safety and outcomes.

4. Stepwise DAPT De-escalation in DCB-Only PCI for ACS

In the REC-CAGEFREE II trial, a stepwise de-escalation of dual antiplatelet therapy (DAPT) was tested in patients undergoing drug-coated balloon (DCB)-only PCI for acute coronary syndromes (ACS). The trial aims to optimize patient outcomes by reducing the duration of DAPT, thereby minimizing bleeding risks without compromising the efficacy of the intervention. This study builds upon the existing body of evidence supporting DAPT de-escalation in drug-eluting stent (DES) PCI.

5. SGLT2 Inhibitors in Functional Mitral Regurgitation (MR)

Adding an SGLT2 inhibitor to guideline-directed medical therapy (GDMT) in patients with functional mitral regurgitation (MR) has shown potential in reducing the need for transcatheter edge-to-edge repair (TEER). This approach underscores the importance of optimizing medical therapy before considering invasive procedures, aligning with a growing trend towards comprehensive, non-invasive management strategies in heart failure and associated conditions.

6. ORBITA-2: Predicting PCI Response Based on Angina Phenotype

The ORBITA-2 study provided insights into how angina phenotype can predict a patient's response to PCI. By asking a few simple questions about the nature of symptoms, clinicians can better determine which patients are likely to benefit from PCI. This approach can refine patient selection, improve outcomes, and potentially reduce unnecessary procedures, emphasizing the value of personalized medicine.

7. Remote Monitoring in Heart Failure: TELESAT-HF

The TELESAT-HF study presented observational data suggesting that remote monitoring of weight and symptoms in heart failure patients can significantly reduce all-cause mortality. This finding supports the integration of telemedicine into heart failure management, demonstrating that basic remote monitoring can effectively mitigate patient risks and improve clinical outcomes.

8. Myval TAVI Valve Performance at 30 Days

The Indian-made Myval TAVI valve, available in nine sizes, has shown comparable performance to contemporary TAVI devices at 30 days post-implantation. Experts agree that while these initial results are promising, further randomized trials are needed to assess the long-term efficacy and safety of Myval. The diversity in valve sizes may offer enhanced customization for patient-specific anatomical variations.

9. ShortCut Leaflet Splitter for Valve-in-Valve TAVI

The ShortCut leaflet splitter has been proven safe and effective in lacerating bioprosthetic valve leaflets at risk of causing coronary obstruction during valve-in-valve TAVI procedures. This device provides a quicker and safer alternative to the BASILICA technique, streamlining the procedure and potentially improving patient outcomes in high-risk cases.

10. AID-ANGIO: Beyond Angiography in Chronic Coronary Syndrome (CCS)

The AID-ANGIO strategy advocates for a comprehensive intracoronary testing approach to diagnose conditions like ischemia with no obstructive coronary arteries (INOCA), which are often missed by angiography alone. This hierarchical testing method can enhance diagnostic accuracy and guide appropriate therapeutic interventions, addressing a significant gap in the management of chronic coronary syndrome (CCS).


The top 10 stories of May 2024 from TCTMD reflect the dynamic and rapidly evolving field of interventional cardiology. These articles highlight important clinical trials, innovative procedural advancements, and new therapeutic strategies that are poised to shape the future of cardiovascular care. By staying informed about these developments, healthcare professionals can continue to improve patient outcomes and advance the practice of cardiology.

For more detailed insights and full articles, visit TCTMD’s Top 10 Most Popular Stories for May 2024.

10 views0 comments


bottom of page